Markets:

Overview

News

Currencies

International

Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

353.71 +1.91 (+0.54%)

Streaming Delayed Price Updated: 11:32 AM EST, Feb 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

Alnylam to Webcast Conference Call Discussing Second Quarter 2022 Financial Results

July 18, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Expert Ratings for Alnylam Pharmaceuticals ↗

July 15, 2022

Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter:

Via Benzinga

Alnylam Hits Moderna With Another Patent Infringement Suit-Related To COVID-19 Vaccine ↗

July 15, 2022

Via Benzinga

Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot ↗

July 06, 2022

The company isn't seeking an injunction, but wants "fair compensation."

Via Investor's Business Daily

Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot ↗

July 05, 2022

The company isn't seeking an injunction, but wants "fair compensation."

Via Investor's Business Daily

Analyst Ratings for Alnylam Pharmaceuticals ↗

June 07, 2022

Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter:

Via Benzinga

Alnylam's Lumasiran Shows Clinical Benefit In Rare Kidney Disease ↗

May 24, 2022

Via Benzinga

Why HC Wainwright Is Bullish On This Stock's Hepatitis-B Pipeline ↗

May 02, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2022 ↗

July 13, 2022

Upgrades

Via Benzinga

5 Best And Worst Performing Large-Cap Stocks In June 2022 ↗

July 05, 2022

Over the past decade or so, these large-cap stocks have outperformed their smaller peers. Let’s take a look at the five best and worst performing large-cap stocks in June 2022.

Via Talk Markets

Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates ↗

July 01, 2022

The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.

Via Benzinga

Where Alnylam Pharmaceuticals Stands With Analysts ↗

June 27, 2022

Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 27, 2022 ↗

June 27, 2022

Upgrades

Via Benzinga

The Daily Biotech Pulse: FDA Nod For Lilly-Incyte's Patchy Hair Loss Treatment, First Regulatory Submission For EQRx, Soleno's Promising Data From Prader-Willi Candidate ↗

June 14, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Alnylam's Stock Gains Following FDA Nod For hATTR Amyloidosis Candidate ↗

June 13, 2022

The U.S. Food and Drug Administration (FDA) approved Alnylam Pharmaceuticals’ (NASDAQ: ALNY) lead drug candidate AMVUTTRA (Vutrisiran) for the treatment of the polyneuropathy of hereditary...

Via Benzinga

Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

June 13, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy

June 09, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2022 ↗

June 07, 2022

Upgrades

Via Benzinga

Alnylam to Webcast Presentations at Upcoming June Investor Conferences

June 02, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces Publication of Preclinical Results Based on Novel Conjugate Technology That Facilitates Delivery of Short Interfering RNA to the Central Nervous System and Other Extrahepatic Tissues

June 02, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1

May 24, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Presents New 18-Month Results from Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational Vutrisiran

May 23, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Presentations at Upcoming May Investor Conferences

May 04, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

10 Biggest Price Target Changes For Monday ↗

May 02, 2022

Morgan Stanley boosted Archer-Daniels-Midland Company (NYSE: ADM) price target from $69 to $94. Archer-Daniels-Midland shares fell 0.5% to $89.10 in pre-market trading.

Via Benzinga

Expert Ratings for Alnylam Pharmaceuticals ↗

April 29, 2022

Over the past 3 months, 10 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates ↗

April 28, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Alnylam Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity

April 28, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

What To Know About Morgan Stanley's Downgrade of Alnylam Pharmaceuticals ↗

April 25, 2022

Morgan Stanley downgraded its rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) to Equal-Weight with a price target of $178.00, changing its price target from $210.00 to $178.00. Shares of Alnylam...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022 ↗

April 25, 2022

Via Benzinga

The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More ↗

April 24, 2022

Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering...

Via Benzinga

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.